Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22900884 | 1.00 | GPR119 (0.44) | GPR119CDK4CCND1CCND3CDK6 | |
| SCHEMBL29926792 | 0.91 | CDK4 (0.42) | GPR119CDK4CCND1CCND3CDK6 | |
| SCHEMBL22900807 | 0.86 | NSD2 (0.49) | GPR119PIK3CDUSP30NSD2 | |
| SCHEMBL22900801 | 0.84 | CDK4 (0.44) | GPR119CDK4CCND1CCND3CDK6 | |
| SCHEMBL29820639 | 0.84 | CDK4 (0.44) | GPR119CDK4CCND1CCND3CDK6 | |
| SCHEMBL30449822 | 0.79 | JAK3 (0.41) | GPR119CDK4CCND1CCND3USP30 | |
| SCHEMBL16202671 | 0.77 | SYK (0.47) | JAK3BTK | |
| SCHEMBL16671765 | 0.77 | PIK3CD (0.49) | GPR119CDK4CCND1PIK3CDUSP30 | |
| SCHEMBL25979979 | 0.77 | CCND3 (0.46) | GPR119CDK4CCND1CCND3CDK6 | |
| SCHEMBL23292325 | 0.76 | CCNK (0.61) | PIK3CDUSP30NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472791-B2 | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472791-B2 | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK2AP2, CDK4 | GPR119 3440/4885CDK4 3/4885CCND1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.